Current stock page

Financial Data

NVS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareDrug Manufacturers - GeneralScore data as of Nov 13, 2026

NVSNovartis AG

Healthcare / Drug Manufacturers - General

Low Priority

Above Peers

NeutralEdge 6/10
$160.50+$0.25 (+0.16%)

Latest quote

  • Momentum
    64
  • Value
    49
  • Quality
    58
  • Risk resilience
    76
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-292025-06-302025-03-312024-12-31
Revenue$15.03B$14.42B$13.52B$13.33B$14.36B$14.84B$13.62B$13.56B
Gross Profit$11.42B$10.74B$10.07B$9.79B$10.82B$11.51B$10.39B$10.23B
Operating Income$1.84B$4.74B$4.24B$3.52B$4.5B$4.86B$4.66B$3.53B
Net Income$1.2B$3.27B$3.16B$2.41B$3.93B$4.04B$3.61B$2.82B
EPS$0.63$1.71$1.65$1.26$2.04$2.07$1.83$1.42
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-292025-06-302025-03-312024-12-31
Operating Cash Flow$5.5B$5.89B$3.68B$2.25B$6.57B$6.66B$3.65B$4.19B
Capital Expenditure-$742M-$321.07M-$807M-$610.9M-$831M-$558M-$1.49B-$1.13B
Free Cash Flow$4.76B$5.57B$2.87B$1.64B$5.74B$6.11B$2.15B$3.06B
Net Cash Provided By Operating Activities$5.5B$5.89B$3.68B$2.25B$6.57B$6.66B$3.65B$4.19B
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-292025-06-302025-03-312024-12-31
Total Assets$117.15B$122.03B$118.53B$115.57B$107.29B$104.4B$99.94B$102.25B
Total Debt$48.31B$49.01B$47B$37.11B$32.02B$32.64B$31.27B$31.26B
Cash And Cash Equivalents$8.87B$7.62B$6.88B$11.44B$9.56B$6.66B$7.07B$11.46B
Total Liabilities$79.59B$80.09B$79.61B$69.02B$62.54B$62.34B$61.49B$58.12B
Total Stockholders Equity$37.23B$41.54B$38.51B$46.13B$44.33B$41.99B$38.37B$44.05B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-292025-06-302025-03-312024-12-31
P/E ratio29.7823.0820.6——32.72——
P/B ratio8.037.097.24——5.35——
P/S ratio5.4———————
Debt To Equity1.31.181.220.80.720.780.810.71
Free Cash Flow Yield4.97%5.37%5.87%——4.08%——
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-292025-06-302025-03-312024-12-31
P/E ratio29.7823.0820.6——32.72——
P/B ratio8.037.097.24——5.35——
P/S ratio5.4———————
Return On Equity26.95%30.71%35.14%30.31%32.47%32.52%33.51%27.11%
Debt To Equity1.31.181.220.80.720.780.810.71

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe30.72x
Pb8.1x
Revenue Growth Yoy4.67%
EPS Growth Yoy-69.12%
Gross Margin74.30%
Operating Margin30.47%
ROE24.24%
ROIC13.96%
Debt To Equity1.3
FCF Yield5.08%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$160.50
Volume1.42M
RSI (14)58.46
MACD3.49
MACD signal3.79
MACD histogram-0.3
ADX (14)25.63
SMA (50)$149.13
SMA (200)$152.57
ATR (14)$3.05
Historical volatility (annualized)27.38%
Volume (20-day average)2.19M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score76/100
Beta0.37
Annual volatility27.23%
Max Drawdown-18.66%
Sharpe Ratio0.72
VaR (95%, 1-day)-2.24%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

NVS Financial Data FAQ

What is Novartis AG's revenue?

Novartis AG's revenue is one of the core financial data points for NVS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Novartis AG's revenue growing?

Revenue growth shows whether Novartis AG is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is NVS's EPS?

NVS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Novartis AG's net income?

Novartis AG's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Novartis AG generate?

Free cash flow shows how much cash Novartis AG generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Novartis AG have?

Cash and debt help frame NVS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.